EventsThe 2nd International Electronic Conference on Vaccines
Published
This submission belongs to the session S2. Challenges of Developing a Dengue Vaccine of the event The 2nd International Electronic Conference on Vaccines
Published date
25 Nov, 2024
Academic Editor
author-avatarHenry Puerta-Guardo
Citation
Hector Hernando Gutierrez Barbosa, Sandra Medina-Moreno, Federico Perdomo-Celis, Harry Davis, Joel Chua, Juan C Zapta, A comparison of Humanized mice models using NOD-derived strains for Dengue virus infection, in Proceedings of The 2nd International Electronic Conference on Vaccines, 27 November–29 November 2024, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

A comparison of Humanized mice models using NOD-derived strains for Dengue virus infection

Harry Davis 1
1. Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA, USA
2. Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá 110231, Colombia, Colombia
Abstract

Dengue, a major public health issue in tropical and subtropical regions, currently has no specific treatment and only one licensed vaccine, with limited use in endemic areas. The lack of antiviral drugs and the challenges in understanding dengue’s pathophysiology stem from the absence of an effective animal model that mirrors human infection in terms of viraemia peaks, clinical presentation, and immune response. Humanized mouse models have been useful in viral disease research, but dengue studies often use NOD-scid IL2R gamma null (NSG) immunodeficient mice, which focus on preventing graft rejection rather than fully developing human hematopoiesis. In this study, we compare four humanized mouse models derived from NOD mice expressing human cytokines, which were xenotransplanted and infected with DENV-2 (New Guinea C) intravenously. The models (Hu-NSG, hu-EXL, hu-SGM3) received xenotransplants of CD34+ fetal cord blood, while one model (Hu-SGM3-PBMCs) was transplanted with human PBMCs. We found that models expressing human cytokines had higher viremia compared to the NSG model. All the models showed infectious virus during viremia, confirmed by means of indirect plaque assays. The Hu-SGM3-PBMCs model, in particular, developed a severe infection with signs of bleeding and intestinal necrosis, leading to the death of all mice by day 18 post-infection, with viremia levels twice as high as in the other models according to RT-qPCR. The models using hCD34+ cells showed low or undetectable levels of human proinflammatory cytokines during infection, measured by means of flow cytometry Bead Arrays. In contrast, the hu-mice model with human PBMCs exhibited detectable and decreasing levels of IFN-g, IL-10, IP10, and TNF, which is consistent with the immune modulation seen in DENV-2 New Guinea C strain infections. These results indicate that humanized mice models derived from NOD mice expressing human cytokines enhance viremia and offer a relevant platform for studying dengue and potential treatments.

Keywords
Humanized mice models
Dengue virus
NSG
NCG
NOG-EXL
NSG-SGM3
xenograft
CD34+
PBMCs.
Turbo: an adjuvant platform for bacterial glycoconjugate vaccines
Efficacy, Safety, and Molecular Mechanism of Sublingual Poly(I:C)-Adjuvanted Vaccine Formulated with SARS-CoV-2 RBD or Influenza HA Antigen in Non-Human Primates, Macaque Monkeys